It is seen in approximately 80% of WHO grade II/III gliomas [86,98,99] and in 4–12% of GBM [87,90,99], whereas only a minority of gliomas (4–8%) harbor an IDH2 mutation [86,98,100] (Figure 2a). The gene discussed is IDH2; the disease is central nervous system cancer.